Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12613000856718
Ethics application status
Approved
Date submitted
30/07/2013
Date registered
2/08/2013
Date last updated
23/10/2015
Type of registration
Prospectively registered
Titles & IDs
Public title
Metformin for Mind and Metabolism
Query!
Scientific title
Metformin for Mind and Metabolism: The effect of metformin 2000mg/day on mood and cognition in adults with treatment resistant depression and abdominal obesity: a pilot randomized placebo controlled trial over 12 weeks.
Query!
Secondary ID [1]
282925
0
Nil
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
The MMM study
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Depression
289742
0
Query!
Abdominal Obesity
289743
0
Query!
Condition category
Condition code
Mental Health
290073
290073
0
0
Query!
Depression
Query!
Diet and Nutrition
290107
290107
0
0
Query!
Obesity
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Metformin 2 x 500mg oral tablets twice daily for 12 weeks (total daily dose 2000mg). Adherence will be monitored by counting drug returns on a monthly basis.
Query!
Intervention code [1]
287627
0
Treatment: Drugs
Query!
Comparator / control treatment
Placebo (gelatine capsule filled with lactose powder) oral capsule taken twice daily for 12 weeks
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
290126
0
severity of depression as assessed using the MADRS (Montgomery Asperg Depression Rating Scale)
Query!
Assessment method [1]
290126
0
Query!
Timepoint [1]
290126
0
12 weeks
Query!
Secondary outcome [1]
303978
0
change in cognition as measured by CogState (computer based cognitive testing)
Query!
Assessment method [1]
303978
0
Query!
Timepoint [1]
303978
0
12 weeks
Query!
Secondary outcome [2]
303979
0
change in weight as determined by using calibrated digital scales
Query!
Assessment method [2]
303979
0
Query!
Timepoint [2]
303979
0
12 weeks
Query!
Eligibility
Key inclusion criteria
adults aged 18-65
ongoing symptoms of depression (MADRS>10) despite at least 8 weeks on a stable dose of an antidepressant
adbominal obesity (waist circumference >88cm for women or 102cm for men)
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
renal impairment (eGFR<60)
suicidal
psychotic disorders
diabetes mellitus
allergy to metformin, lactose or other component of metformin or placebo formulations
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
2/09/2013
Query!
Actual
16/06/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
30
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Funding & Sponsors
Funding source category [1]
287705
0
Charities/Societies/Foundations
Query!
Name [1]
287705
0
Preston and Loui Geduld Charitable Trust
Query!
Address [1]
287705
0
Equity Trustees
Level 2, 575 Bourke St
Melbourne VIC 3000
Query!
Country [1]
287705
0
Australia
Query!
Primary sponsor type
Hospital
Query!
Name
The Alfred Hospital
Query!
Address
Commercial Rd
Prahran
Melbourne VIC
3181
Query!
Country
Australia
Query!
Secondary sponsor category [1]
286435
0
None
Query!
Name [1]
286435
0
None
Query!
Address [1]
286435
0
Query!
Country [1]
286435
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
289662
0
The Alfred Hospital Ethics Committee
Query!
Ethics committee address [1]
289662
0
The Alfred Hospital
Commercial Rd
Prahran VIC
3181
Query!
Ethics committee country [1]
289662
0
Australia
Query!
Date submitted for ethics approval [1]
289662
0
31/07/2013
Query!
Approval date [1]
289662
0
20/09/2013
Query!
Ethics approval number [1]
289662
0
126/13
Query!
Ethics committee name [2]
293741
0
Monash University Human Research Ethics Committee
Query!
Ethics committee address [2]
293741
0
Query!
Ethics committee country [2]
293741
0
Australia
Query!
Date submitted for ethics approval [2]
293741
0
Query!
Approval date [2]
293741
0
30/10/2013
Query!
Ethics approval number [2]
293741
0
CF13/3101 - 2013001644
Query!
Summary
Brief summary
Metformin is a medication originally derived from French Lilac which has been used to treat diabetes for over 50 years. The aim of this study is to see whether metformin can improve mood and memory in people who have depression and obesity. We will recruit 30 adults who feel depressed despite currently taking an antidepressant medication and who also have a large waist measurement (more than 88cm for women and 102cm for men). The study will last for 12 weeks. Participants will be randomized to either metformin 1000mg twice per day with food or placebo. At the beginning and the end of the study mood will be rated by self-report and by the doctor’s impression. Memory will be measured using a series of computer based tests, similar to playing simple computer games. The hope is that metformin will help obese adults with depression by reducing levels of the hormone insulin as well as markers of inflammation, within the brain, thereby improving mood.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
41846
0
Dr Roisin Worsley
Query!
Address
41846
0
Monash Alfred Psychiatry Research Centre
Level 4
607 St Kilda Rd
Melbourne VIC 3004
Query!
Country
41846
0
Australia
Query!
Phone
41846
0
+61 3 9076 6564
Query!
Fax
41846
0
Query!
Email
41846
0
[email protected]
Query!
Contact person for public queries
Name
41847
0
Dr Roisin Worsley
Query!
Address
41847
0
Monash Alfred Psychiatry Research Centre
Level 4
607 St Kilda Rd
Melbourne VIC 3004
Query!
Country
41847
0
Australia
Query!
Phone
41847
0
+61 3 9076 6564
Query!
Fax
41847
0
Query!
Email
41847
0
[email protected]
Query!
Contact person for scientific queries
Name
41848
0
Dr Roisin Worsley
Query!
Address
41848
0
Monash Alfred Psychiatry Research Centre
Level 4
607 St Kilda Rd
Melbourne VIC 3004
Query!
Country
41848
0
Australia
Query!
Phone
41848
0
+61 3 9076 6564
Query!
Fax
41848
0
Query!
Email
41848
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF